Vimian Group AB (publ) - Deep Dive Research Report

Ticker: VIMIAN.ST (Nasdaq Stockholm, Large Cap) | Sector: Healthcare (Animal Health) | Report date: 2026-06-15

Reporting cadence: Quarterly. The five most recent reporting periods used throughout this report are Q1 2025 (call Apr 30 2025), Q2 2025 (Jul 18 2025), Q3 2025 (Oct 22 2025), Q4/FY 2025 (Feb 12 2026), and Q1 2026 (Apr 29 2026). The most recent call is within ~90 days of today.

Section 1: What the Company Does

Vimian is an animal health company. It sells the medicines, surgical hardware, lab diagnostics, and back-office services that veterinary clinics and animal labs need to actually run their business. If a dog has a chronic skin allergy, a Vimian product treats it. If that dog needs a cruciate-ligament repair, a Vimian-made bone plate and the surgeon's instruments come from Vimian. If a farm lab needs to test a herd for a viral outbreak, a Vimian diagnostic kit runs the assay. And if the clinic owner wants better purchasing terms, marketing, and staff training, a Vimian membership platform provides it. The company is deliberately spread across four corners of the same building: the animal, the procedure, the lab, and the clinic-as-a-business.

The founding story explains the shape of the company better than any product description. Vimian is the creation of Fidelio Capital, a Stockholm private equity firm that began buying animal-health businesses in 2015. Fidelio did not start one company and grow it; it ran four parallel buy-and-build platforms, each consolidating a fragmented niche. Nextmune (specialty pharma, allergy and dermatology) was assembled from 2015 onward out of companies in the Netherlands, Spain, Belgium, Norway, the US, and Italy. Movora (veterinary orthopedics and dental) was built in 2019-2020 from three businesses in Switzerland and the US. VetFamily (a clinic membership platform) and Indical Bioscience (veterinary diagnostics) rounded out the set. In 2021 Fidelio gathered all four under one holding company, Vimian Group AB, and floated it on Nasdaq First North Growth Market on 18 June 2021. By 2021 the group had already absorbed around 20 companies; by late 2025 management cited roughly 44 acquisitions over five years. In 2025 the share moved up to the Nasdaq Stockholm main market (Large Cap).

So the core value proposition has two faces. To the veterinary professional, Vimian is a supplier of specialist products that a general distributor does not carry well: niche dermatology drugs, orthopedic implants, lab assays for specific pathogens. To Fidelio and public shareholders, Vimian is a permanent-capital vehicle for consolidating animal health, a sector with attractive economics (pet owners pay out of pocket, demand is recession-resilient, the installed base of pets keeps growing) and thousands of small entrepreneur-owned businesses to roll up.

The thing that makes the model hard to replicate is not any single product. It is the combination of four deep, regulated, relationship-driven niches under one disciplined acquirer that knows how to buy founder-owned companies, keep the founders, and cross-sell across the platform. A new entrant cannot assemble Nextmune's allergen library, Movora's implant catalogue, and VetFamily's clinic network by writing one cheque.

Management frames cross-selling as the engine that turns a collection of acquisitions into one company: in Q3 2025 (Oct 22 2025) they noted that 39% of year-to-date organic growth came from cross-selling initiatives, with eight new cross-selling programs scheduled for 2026.

Section 2: Business Segments

Vimian reports four segments. Each was a separate Fidelio platform before 2021, which is exactly why they exist as distinct units: different technology, different customers, different regulation, different acquisition lineage. Approximate revenue mix is Specialty Pharma ~46%, MedTech ~31%, Veterinary Services ~14%, and Diagnostics ~9%.

Specialty Pharma (brand: Nextmune) - the engine, ~46% of revenue

What it does: Nextmune develops and sells proprietary diagnostics and prescription and non-prescription treatments for companion animals, concentrated in four therapeutic areas: allergy, dermatology, otology (ear conditions), and specialized nutrition. Its signature capability is allergen immunotherapy - testing a pet for what it is allergic to, then formulating a custom desensitizing treatment. The flagship product family includes Peptivet (ear-infection treatment using patented peptides; Peptivet 4 was highlighted as a new launch).

Core capability: A library of allergens and the formulation know-how to make individualized immunotherapy at scale, plus a registered product portfolio across many countries. Allergy and dermatology are chronic conditions, so once a pet is on a Nextmune protocol the revenue recurs for years. The segment launches a high cadence of products (23 new products in Q1 2025, 21 in Q3 2025, with ~70 in the pipeline), which is unusual for a company this size and is the source of its consistent double-digit organic growth.

Why it's separate: Pharma is the most heavily regulated and highest-margin part of the group, with its own R&D and registration machinery. It is the only segment management explicitly calls a structural double-digit organic grower.

Competitive position: Competes with the dermatology and specialty arms of Zoetis, Elanco, Virbac, Vetoquinol, and Dechra. Nextmune wins on focus and breadth within allergy/dermatology specifically, an area the giants treat as one line among many.

How it fits: This is the margin engine and the growth anchor. Management has said it views Specialty Pharma as a double-digit organic grower and has cited ~12% average quarterly growth since the IPO (Q3 2025).

MedTech (brand: Movora) - the cyclical second pillar, ~31% of revenue

What it does: Movora supplies surgical and dental products to veterinary clinics and universities - companion-animal orthopedic implants (bone plates, screws, the hardware for fracture and cruciate-ligament repair) and a growing veterinary dentistry portfolio, including AI-enabled dental imaging software. It markets one of the broadest product ranges in veterinary dentistry and companion-animal orthopedics.

Core capability: Surgical-grade manufacturing, a comprehensive implant system, and - critically - clinician education. Veterinary surgeons must be trained on a specific implant system; once trained, they keep using it. Movora invests heavily in surgeon education in the US to build that installed base.

Why it's separate: It is medical-device manufacturing and surgical sales, a completely different discipline from pharma or lab assays, with device regulation rather than drug regulation.

Competitive position: Competes against other veterinary orthopedic-implant makers and the surgical lines of larger players. It wins on portfolio breadth and surgeon relationships; it loses to the broader macro - elective surgery volumes.

How it fits: This is the group's cyclical exposure and its current problem child. US orthopedics is tied to elective-surgery demand, which has been soft, and an "annual order program" (AOP) distortion hit it in early 2025. Management has been investing in the US commercial organization and consolidating dental acquisitions (different, lower margin profile), which compressed segment margins.

Veterinary Services (brand: VetFamily) - the network bet, ~14% of revenue

What it does: VetFamily is a membership platform for independent veterinary clinics. It aggregates clinics' purchasing power (procurement), and layers on technology-driven operational services: online marketing, education, HR support, and a professional community. It reached roughly 9,940 member clinics by Q3 2025 and adds hundreds per quarter (240 in Q3 2025).

Core capability: A large, sticky network of clinics. The more clinics join, the better the procurement terms VetFamily can negotiate, and the more valuable the platform becomes - a flywheel. It is also the natural distribution channel for the rest of Vimian's products.

Why it's separate: It is a services/platform business with software-and-membership economics, not a product manufacturer. Its strategic role is distribution and stickiness, not product margin.

Competitive position: Competes with corporate clinic chains (which buy and own clinics outright) and with general distributors. VetFamily's pitch is the opposite of the corporate-chain model: stay independent, keep ownership, get the buying scale. It is expanding into new geographies (Italy, Denmark, Ireland), which depresses near-term margin.

How it fits: A strategic option and a distribution layer. Margins swing with geographic-investment cadence (jumped from ~25% to ~30% in Q1 2025, then declined year-over-year in Q3 2025 as new-market investment ramped).

Diagnostics (brand: Indical Bioscience) - the smallest, most volatile, ~9% of revenue

What it does: Indical provides molecular and immunodiagnostic solutions used by veterinary laboratories, with a focus on livestock and companion-animal health. These are the kits and reagents that labs run to detect specific pathogens.

Core capability: Assay development and a portfolio of validated tests for veterinary-specific pathogens, especially in livestock.

Why it's separate: Lab diagnostics is its own technology and customer base (labs, not clinics) and its demand is partly driven by disease outbreaks, which makes it the most volatile segment.

Competitive position: Competes against the diagnostics arms of IDEXX (the dominant veterinary diagnostics player), Zoetis, and others. Indical is a niche/livestock-tilted player rather than a companion-animal point-of-care competitor to IDEXX.

How it fits: The smallest segment and a swing factor. Q3 2025 organic growth dropped to 4% on lower disease outbreaks, and segment profit fell sharply, illustrating its outbreak-dependent demand.

Segment summary

Section 3: Products and Business Detail

The catalogue spans four very different product families. In Specialty Pharma, the core is allergen-specific immunotherapy (test the animal, formulate a custom desensitizing treatment for chronic allergy), supported by dermatology and otology lines such as the Peptivet ear-infection range built on patented peptides, plus specialized veterinary nutrition. The segment's distinguishing operating characteristic is its launch cadence: dozens of new products per year against a standing pipeline of around 70, which is how a mid-cap sustains double-digit organic growth without relying solely on M&A.

In MedTech (Movora), the products are physical surgical goods: titanium/steel orthopedic implants (plates, screws, fixation systems) for fracture repair and the very common canine cruciate-ligament procedure, the surgical instruments to place them, and a dentistry portfolio that now includes AI-enabled imaging software. These are regulated medical devices that must be manufactured to surgical-grade standards. The binding constraint is not manufacturing capacity but adoption: a surgeon has to be trained on the system, which is why Movora's spend goes into clinician education, especially in the US.

In Veterinary Services (VetFamily), the "product" is the membership itself plus a stack of services - group procurement, digital marketing, continuing education, HR tools, and a peer community - delivered through a platform that gets more valuable as clinic count grows.

In Diagnostics (Indical), the products are molecular (PCR-type) and immunodiagnostic test kits and reagents for veterinary pathogens, sold to laboratories, with a livestock tilt.

Geography and operations: Vimian reaches veterinary clinics and laboratories in over 80 markets, with roughly 1,300 employees, and is headquartered in Stockholm. Nextmune's manufacturing and operating footprint reflects its acquisition history across the Netherlands, Spain, Belgium, Norway, the US, and Italy; Movora's sits in Switzerland and the US. The US is a material market for MedTech orthopedics and is the focus of both the elective-surgery softness and the dental roll-up. Recent expansion has added operations in Italy, Denmark, and Ireland, with planned entries into Japan and Portugal.

Notable milestones: Nextmune assembled from 2015; Movora built 2019-2020; Vimian Group formed and IPO'd on Nasdaq First North in June 2021 with SEK 5.1bn of cornerstone interest; move to Nasdaq Stockholm Large Cap in 2025; roughly 44 acquisitions completed over five years; a dental-focused acquisition sprint (four deals in twelve months) to build the dentistry portfolio.

Section 4: Customers

Vimian's customers are veterinary clinics, veterinary surgeons and universities, and veterinary laboratories - plus, indirectly, the pet owners who ultimately pay. There is essentially no single dominant customer; the base is fragmented across more than 80 markets and thousands of clinics, which is a deliberate feature of an animal-health business and the opposite of a concentration risk.

The buying decision differs by segment, and so do the switching costs:

• Specialty Pharma: The prescriber is the veterinarian, and the buyer of a chronic-allergy protocol is the pet owner who pays out of pocket. The criterion is clinical efficacy and the vet's familiarity with the protocol. Switching cost is moderate-to-high for an animal already stabilized on an immunotherapy regimen - you do not change a working chronic treatment lightly. This is the most recurring revenue in the group.
• MedTech: The decision-maker is the operating surgeon, and the criterion is what implant system they were trained on. Switching cost is high in the best way: once a surgeon learns Movora's system through Movora's education, they keep buying the consumable implants. The sales cycle is long because it runs through training, not a purchase order.
• Veterinary Services: The decision-maker is the clinic owner/practice manager, and the criterion is procurement savings plus the value of the marketing/HR/education stack. Switching cost grows with tenure as the clinic integrates VetFamily's services and procurement into daily operations. Revenue is membership-recurring.
• Diagnostics: The buyer is the laboratory, choosing on assay validation, sensitivity, and breadth. Switching cost is real (labs validate assays into their workflow) but demand is event-driven by disease outbreaks.

Contract structure across the group skews toward recurring and consumable revenue (chronic prescriptions, implant consumables tied to an installed surgeon base, recurring memberships, repeat lab reagents) rather than one-off capital sales. That is what gives the model its predictability and why management can speak confidently about structural double-digit growth in pharma. The main predictability gap is MedTech, where elective-surgery volumes flex with the macro, and Diagnostics, where outbreaks are unforecastable.

Section 5: Competitive Landscape

Vimian sits in animal health, a sector dominated by a handful of very large, mostly US-listed players, with Vimian competing not as a generalist giant but as a focused consolidator inside specific niches. It does not go head-to-head with Zoetis across the whole market; it competes segment by segment.

In Specialty Pharma, the relevant competitors are the dermatology/specialty lines of Zoetis, Elanco, Virbac, Vetoquinol, and (until its 2024 take-private) Dechra. Vimian's edge is concentration in allergy/dermatology/otology, where it has a deeper dedicated portfolio than any single line inside a diversified giant; its exposure is that the giants have vastly larger R&D budgets and salesforces.

In MedTech, the field is veterinary orthopedic-implant and dental-device specialists, many of them private; Vimian (Movora) is one of the broader players, winning on portfolio breadth and surgeon training and losing to elective-surgery cyclicality rather than to a specific rival.

In Diagnostics, the dominant force is IDEXX, which owns companion-animal point-of-care diagnostics; Indical avoids that head-on fight by tilting toward livestock and lab-based molecular assays.

In Veterinary Services, the competition is structural rather than a named rival - the corporate clinic-roll-up chains and the large distributors (Covetrus, Henry Schein/Patterson on the distribution side). VetFamily's whole pitch is the anti-chain: keep ownership, gain scale.

Barriers to entry are real but niche-specific rather than a single wide moat: regulatory registration of drugs and devices country by country, an allergen library and formulation know-how in pharma, a trained surgeon installed base in MedTech, assay validation in diagnostics, and network density in services. The structural shift underway is consolidation - the sector has been a rich hunting ground for both strategics and private equity (Dechra taken private by EQT in 2024, Heska acquired into Mars/Antech, Covetrus taken private in 2022). Vimian is itself an instrument of that consolidation. Where Vimian is strong is focus and acquisition discipline; where it is exposed is sheer scale disadvantage against Zoetis/IDEXX and dependence on continued M&A to sustain its growth algorithm.

Market-cap figures are approximate peer-size references as of mid-2026 and move with the market; they are shown only to convey relative scale.

Section 6: Industry

Demand for animal health is driven by the size and "humanization" of the pet population and by livestock production. Pet owners increasingly treat animals as family and pay out of pocket for chronic care, surgery, and diagnostics, which makes companion-animal health structurally growing and relatively recession-resilient (people cut many things before cutting the dog's allergy medication). On the livestock side, demand tracks herd health, food-safety regulation, and disease-outbreak cycles.

On size: the global animal health market was valued at roughly USD 62bn in 2024 and is projected toward USD 100bn+ over the next decade (Grand View Research). The companion-animal drugs sub-market was around USD 27bn in 2025, with the top five players (Zoetis, Boehringer Ingelheim, Elanco, Merck, Virbac) holding ~68% and Zoetis alone over 28% (GMInsights). Companion-animal diagnostics is projected to grow from ~USD 3.0bn (2024) to ~USD 4.6bn (2029), an ~8.8% CAGR, led by IDEXX and Zoetis (MarketsandMarkets). Vimian operates in the higher-growth specialty and services pockets of this market rather than the commoditized mass-vaccine core.

Within the supply chain, Vimian is a manufacturer and distributor of specialty products plus a services/network layer - it sits between the basic-chemistry suppliers and the clinic, in the value-added specialty tier. Regulation is a defining feature: drugs require national registration, devices require medical-device approval, and these approvals are both a cost and a barrier protecting incumbents. The industry is fragmented at the niche level (thousands of small specialist and clinic businesses), which is precisely the condition that makes roll-up strategies like Vimian's viable.

Cyclicality is mixed: pharma and services are stable, MedTech (elective surgery) is mildly cyclical with discretionary pet spending, and diagnostics swings with disease outbreaks. Tailwinds: pet humanization, rising spend per animal, an aging pet population needing chronic care, and ongoing consolidation. Headwinds: pricing/affordability pressure on pet owners, the UK veterinary-market transparency review (which management flagged as immaterial to Vimian), and trade/tariff friction on US-linked product flows.

Section 7: Growth Triggers

All items are drawn from the five concall transcripts and presentations, cited to the specific call.

• Specialty Pharma double-digit organic growth maintained through 2026. (Q1 2026 call, Apr 29 2026; repeated from Q3 2025, Oct 22 2025)

  "We definitely view Specialty Pharma as a double-digit organic growth business." (Q3 2025, Oct 22 2025)

• Eight new cross-selling programs launching in 2026, on top of the 39% of year-to-date organic growth that cross-selling already contributed. (Q3 2025 call, Oct 22 2025)
• New-market entries into Japan and Portugal planned for Q3 2026. (Q1 2026 call, Apr 29 2026)
• Veterinary Services geographic expansion into Italy, Denmark, and Ireland, supported by three completed acquisitions year-to-date. (Q1 2026 call, Apr 29 2026)
• MedTech US orthopedics recovery expected in spring 2026 after a soft period. (Q1 2026 call, Apr 29 2026) - note this is a repeated/rolling promise; see Walk the Talk.
• Continued bolt-on M&A pipeline. Management cited 235 targets screened year-to-date and an "acceleration" of pipeline efforts across existing platforms and new niches. (Q3 2025 call, Oct 22 2025)

  "We're accelerating our efforts to advance and progress our pipeline, covering both existing platforms and new market niches." (Q3 2025, Oct 22 2025)

• Dental portfolio build-out, including the recent acquisition of AI-enabled dental imaging software and four dentistry acquisitions over twelve months. (Q3 2025 call, Oct 22 2025)
• High new-product cadence in Specialty Pharma: ~70 products in the pipeline, including Peptivet 4 with patented peptides for ear infections. (Q3 2025 call, Oct 22 2025)
• Long-term financial target of EUR 300m adjusted EBITDA by 2030, with leverage kept at or below 3.0x. (Q3 2025 call, Oct 22 2025)

Section 8: Key Risks

Management instability. This is the most company-specific risk right now and it is acute. In the space of roughly a year Vimian lost its CEO (Patrik Eriksson departed around Q2 2025), ran with the CFO as interim CEO, appointed a new CEO from inside (Alireza Tajbakhsh, previously head of Veterinary Services, late 2025), saw its Head of Specialty Pharma (Magnus Kjellberg) leave - with the CFO again stepping in as interim head of the most important segment - and brought in a new Head of MedTech (Lotta Lundaas). When the CFO is simultaneously running finance and a segment, execution bandwidth is stretched. The mechanism: an acquisition-led growth model depends entirely on management capacity to source, integrate, and cross-sell; churn at the top directly threatens that engine.

Dependence on continued M&A. Vimian's reported growth blends organic and acquired revenue. The EUR 300m-by-2030 target implicitly assumes a steady flow of deals at sensible prices and clean integration. The risk plays out if deal multiples rise (the sector is being chased by EQT, Mars, and others), if a large integration goes wrong, or if leverage (held around 2.1x against a 3.0x ceiling) constrains future buying. A roll-up that stops buying re-rates to its organic growth, which outside Specialty Pharma is mid-single-digit.

MedTech US orthopedics cyclicality. US elective surgery has been soft and the recovery has been promised repeatedly. The mechanism: discretionary pet-surgery volumes flex with consumer health, and Vimian has been investing into the US commercial organization while revenue is weak, so margins compress on both sides. Management itself flagged the softness:

"The surgery market is likely to remain soft over the coming period." (Q3 2025 call, Oct 22 2025)

Controlling shareholder concentration. Fidelio Capital owns roughly 55% of the capital and a majority of votes. Minority holders are along for the ride on capital allocation, related-party dynamics, and any future exit. This cuts both ways - Fidelio's alignment is high (see insider buying) - but the governance risk is real: minorities cannot outvote the sponsor.

US tariff exposure. Management disclosed that about half of US sales are exposed to tariffs, with an estimated low-single-digit-percentage-point impact on 2025 adjusted EBITDA (Q1 2025 call, Apr 30 2025). A meaningful escalation would scale that drag.

Diagnostics outbreak dependence. The smallest segment's demand is partly outbreak-driven; a benign disease environment depresses both growth and segment profit, as seen in Q3 2025. Low impact at group level given the segment's ~9% weight, but it adds quarter-to-quarter noise.

Dilution from incentive programs and equity issuance. Vimian funds growth with equity (a 51.7m-share directed issue raising ~SEK 1.5bn) and runs recurring LTIPs (class D/E share issuance and repurchase). Share count drifts up, which dilutes per-share value if acquired growth does not outrun it.

Section 9: Walk the Talk

The five calls used: Q1 2025 (Apr 30 2025, CEO Patrik Eriksson), Q2 2025 (Jul 18 2025, interim CEO Carl-Johan Zetterberg Boudrie after Eriksson's departure), Q3 2025 (Oct 22 2025, interim CEO Boudrie), Q4/FY 2025 (Feb 12 2026, new CEO Alireza Tajbakhsh with CFO Boudrie), and Q1 2026 (Apr 29 2026, CEO Tajbakhsh).

The dominant story across these five calls is management turnover, and it colours every credibility judgment. The team that made the early-2025 promises is largely not the team being held to them by 2026 - which is itself a finding.

Start with Q1 2025. CEO Patrik Eriksson framed the US orthopedics weakness as transitory and committed to beating the market:

"The US Orthopedics market shrank by low-single digits in Q1. We expect to outperform the market in the remainder of 2025 by leveraging our clinician education efforts." (Q1 2025 call, Apr 30 2025)

He also drew a clean line under the annual order program distortion:

"Yes, this is the last quarter affected by the AOP program. The impact in Q1 was EUR3 million, and we have transitioned to a normalized order flow." (Q1 2025 call, Apr 30 2025)

By Q2 2025, Eriksson had departed and the CFO was running the company on an interim basis. Far from outperforming, MedTech orthopedics declined about 4% organically. The "outperform the market" promise was not met, and the person who made it was gone within a quarter. The AOP claim, to be fair, broadly held - the early-2025 drag did not recur as a fresh surprise.

By Q3 2025, MedTech had recovered to roughly 5% organic growth, which is a genuine delivery against the recovery narrative, though management simultaneously cautioned that the surgery market would stay soft. Specialty Pharma, the most-promised segment, delivered exactly as advertised - double-digit organic growth (11%), consistent with the "we view this as a double-digit business" framing repeated across every call. This is the cleanest kept promise in the set: across all five calls, Specialty Pharma did what management said it would.

By Q4/FY 2025, a third CEO in the period (Tajbakhsh, promoted internally) presented the full year. The group hit roughly mid-single-digit organic growth for the year with double-digit reported growth from acquisitions - in line with the buy-and-build algorithm management describes, nothing dramatically above or below. The Board again proposed no dividend, consistent with the stated reinvestment policy since IPO. On capital allocation, management has been completely consistent: they said they would reinvest in M&A and not pay dividends, and they have done exactly that.

By Q1 2026, the US orthopedics recovery was again pushed forward - now expected in "spring 2026" - which makes it a rolling promise that has slipped across multiple calls. Specialty Pharma again delivered double-digit growth, and management reaffirmed it would continue through 2026. New-market entries (Italy, Denmark, Ireland completed; Japan, Portugal coming) match the expansion cadence they had guided.

A trackable record:

Assessment: On the things management controls structurally - Specialty Pharma growth, the M&A cadence, capital-allocation policy, leverage discipline - this is management that does what it says. On the cyclical wildcard it does not control well - US MedTech orthopedics - it has been consistently too optimistic, promising outperformance and then a recovery that keeps sliding by a quarter or two. The bigger caveat is that the "management" being assessed has changed three times at the CEO level and once at the head of its most important segment inside this window, so the credibility of forward promises rests on a team with a short track record together. Net read: directionally credible and disciplined on capital, but with a habit of over-promising on the one cyclical segment and a leadership-continuity question mark.

Section 10: Shareholder Friendliness Index

Dividends. Vimian has paid no dividend in any of the last three financial years (2023, 2024, 2025). The stated policy is explicit: invest profits and cash flow into organic growth and acquisitions, with no dividend expected in the medium term. The April 2026 AGM again resolved that no dividend be paid for 2025. There is no payout-ratio nuance to add - the payout is zero by design, consistent with a company that IPO'd in 2021 as a growth-by-acquisition vehicle.

Buybacks and dilution. Over the trailing ~90 days, MoatMap records no open-market buyback by Vimian. Over the full three years, there has likewise been no general capital-return buyback program - the only repurchases are mechanical: class D/E shares issued and bought back to fund the long-term incentive programs (the EGM of 11 June 2025 and Board resolutions of 27 October 2025 authorized issuance and repurchase of LTIP shares, e.g. 418,269 class D shares plus class E tranches subscribed at quota value of ~SEK 0.001668). These are dilution-management mechanics for employee incentives, not shareholder returns. On net share count, the direction has been up, not down: a 51.7m-share directed issue raised ~SEK 1.5bn to fund acquisitions, recurring LTIPs add shares, and total shares outstanding stood at roughly 529m as of June 2026. So shares are being created, not retired.

Verdict: Hoards Capital - by explicit design, Vimian pays no dividend, runs no return-oriented buyback, and issues equity to fund M&A; the entire thesis is reinvestment, not capital return.

Section 11: Insider Activities

Source and method. Sweden's primary register is Finansinspektionen's insider register (marknadssok.fi.se), which publishes PDMR transactions under EU MAR Article 19. This section uses the injected MoatMap database block (market: NORDIC) as the spine for the last 12 months, and cross-checks the most recent two weeks against the regulatory/news record; the latest rows (Fitzgerald and Thunell, 9-12 June 2026) are corroborated by news coverage of Vimian insider buying.

The 12-month picture is strongly skewed to buying: 26 buys against 2 sells across 8 distinct insiders, with a pronounced cluster of open-market purchases in early-to-mid June 2026.

Buys - the signal. The standout is Gabriel Fitzgerald, Vimian's Chairman and a founder/managing partner of Fidelio Capital (the controlling ~55% shareholder), buying roughly 1.7m shares across 9-11 June 2026 for approximately SEK 48m in open-market purchases. This is the single largest insider purchase in the past year, reported as the biggest insider buy of Vimian in that span, and it comes from someone already enormously exposed who also refrains from board fees. When the controlling owner adds ~SEK 48m on top of a majority stake, that is a very bullish signal - it is conviction, not compensation. It is reinforced by cluster buying: in the same June window the CEO (Tajbakhsh) and a board member (Ehn) also bought in the open market, and another senior executive (Thunell) bought on 12 June. CEO Tajbakhsh had also bought in March 2026. Multiple insiders buying in the same short window, led by the chairman/controlling shareholder, is the strongest configuration this section can show.

A note on the 14 January 2026 transactions: a wide group of insiders (the CEO, CFO, and several board members) recorded "buys" at prices ranging from ~SEK 3.72 to ~SEK 6.93 - far below the ~SEK 24-29 market price at the time. These are not open-market conviction purchases; they are subscriptions/exercises tied to Vimian's long-term incentive program (the class C/D/E hurdle-share and option structures priced near quota value), and should be read as incentive mechanics rather than market signals.

Sells - the why. The only sells in the window are Magnus Kjellberg's two open-market sales on 3-4 March 2026 (~SEK 2.2m combined). Kjellberg was Head of Specialty Pharma; by Q1 2026 the CFO had stepped in as interim head of that segment, indicating Kjellberg's departure. The most likely explanation is a departing-executive disposition rather than a view on the business; the reason is not explicitly disclosed in the filing, so it is stated here as inferred-from-context, not confirmed.

Net assessment. Insiders are decisively net buyers over the last 12 months (26 buys vs 2 sells), and the buying is both broad-based (chairman, CEO, board members, senior execs) and concentrated in a striking June 2026 cluster led by the controlling shareholder's ~SEK 48m open-market purchase. The only selling is a single departing-executive event with a benign likely explanation. This is a bullish insider signal - among the cleanest a report can present, because it pairs cluster buying with a controlling-owner adding to an already-large stake.

Section 12: Scenarios

Bull case. The leadership reshuffle settles, and Tajbakhsh - who ran the fastest-growing segment before taking the top job - proves to be the operator the company needed. Specialty Pharma keeps compounding at double digits as the new-product pipeline (Peptivet and successors) and the eight 2026 cross-selling programs convert the four ex-platforms into one cross-selling machine. MedTech US orthopedics finally turns the corner as elective surgery normalizes and the US commercial investment pays off, and the dental build-out (with AI imaging) becomes a genuine third growth leg. New markets - Japan, Portugal, plus the recently entered Italy, Denmark, Ireland - widen the runway. The M&A engine keeps buying founder-owned niche leaders at sensible multiples while leverage stays comfortably below the 3.0x ceiling, and the company marches toward its EUR 300m adjusted EBITDA-by-2030 target. The June 2026 cluster of insider buying, led by the chairman's ~SEK 48m, turns out to have marked the bottom of a sentiment trough.

Base case. Vimian keeps doing roughly what it has done: Specialty Pharma delivers its reliable double-digit organic growth and carries the group; Veterinary Services grows steadily while geographic-expansion investment keeps its margin lumpy; Diagnostics bounces around with the outbreak cycle; and MedTech stays the swing factor, with the US orthopedics recovery arriving later and softer than each successive guidance implies. Bolt-on M&A continues to add the difference between organic and reported growth, leverage stays disciplined, and no dividend is paid - cash goes back into deals. Leadership stabilizes without drama. The company grows respectably and compounds, neither blowing past expectations nor breaking, with the management-continuity question gradually answered by tenure.

Bear case. The leadership churn proves symptomatic rather than transitional - a fourth senior departure, integration of a sizeable acquisition stumbles, or the CFO's double-hatting as interim segment head signals genuine bench-depth problems. MedTech US orthopedics stays soft for longer than "next spring," and the margin compression from investing into a weak market persists, dragging group profitability. The M&A flywheel stalls because the sector's PE buyers (EQT, Mars, and others) bid deal multiples up, so Vimian either overpays or stops buying - and a roll-up that stops buying gets re-rated to its mid-single-digit organic core outside pharma. Tariffs escalate against the half of US sales exposed. Throughout, the controlling shareholder's ~55% leaves minorities with little say over capital allocation or a future exit. The growth-by-acquisition story, deprived of acquisitions and dinged by a cyclical segment, looks a lot more ordinary than the IPO promised.

Sources

• Vimian Q1 2026 interim report summary - TipRanks via Globe and Mail / TradingView
• Vimian Q1 2026 results - TipRanks
• Vimian Q4 2025 earnings call transcript - Seeking Alpha
• Vimian Q3 2025 earnings call transcript - Investing.com
• Vimian Q3 2025 presentation - Investing.com
• Vimian Q2 2025 earnings call transcript - MarketScreener
• Vimian Q1 2025 earnings highlights - Yahoo Finance / GuruFocus
• Vimian segments page
• Vimian corporate site
• Fidelio Capital - formation of Vimian
• Vimian first day of trading (Movora newsroom)
• Vimian LTIP 2025 share issue/repurchase press release
• Vimian AGM 29 April 2026 (no dividend)
• Vimian dividend policy
• Fidelio Capital acquires 10m shares in Vimian
• Gabriel Fitzgerald June 2026 share purchase - Webull
• Animal Health Market size - Grand View Research
• Companion Animal Drugs Market - GMInsights
• Companion Animal Diagnostics Market - MarketsandMarkets

A note on deliverable format: this environment exposes only web research tools (no file-write), so the report is delivered inline above rather than written to a .md file. If you want, tell me where to place it and I can format it for hand-off, or expand any section (the Q2 2025 transcript and the Seeking Alpha Q4 2025 transcript were blocked by paywalls/anti-bot, so those two periods lean on press summaries and presentation extracts rather than full verbatim transcripts; flag me if you want me to retry those via a different source).